Supercharged immune cells may make bone marrow transplants safer and more effective
NCT ID NCT03533816
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether giving patients extra gamma delta T-cells—a type of immune cell that can kill cancer—after a half-matched bone marrow transplant can improve outcomes. The study includes up to 38 adults with leukemia or myelodysplastic syndromes. The goal is to see if this approach is safe and helps prevent cancer relapse while reducing graft-versus-host disease, a common and serious transplant complication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gamma delta T-cells (a type of immune cell grown in the lab)
What this could lead to
If it works, this could improve the success of half-matched bone marrow transplants by helping the new immune system attack cancer cells while reducing harmful side effects.
What could go wrong
This is an early phase 1 trial with only 38 participants, so safety and effectiveness are not yet proven. There is a risk of severe side effects, including graft-versus-host disease or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Medical Center
RECRUITINGColumbus, Ohio, 43210-1238, United States
-
University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••